‘Revolutionary’: James Island pharmacist weighs in on newly approved medication
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
2 Minute Medicine3d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
Healthcare Dive24d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
Last month, the Food and Drug Administration approved that molecule, now called Journavx, as a treatment for the sharp, short-lived “acute” pain usually felt after an accident or a surgery.
WebMD28d
Managing Acute Pain With Journavx
Acute pain is a type of pain that comes on quickly but lasts a short amount of time. Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to ...
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...